Latest News - Aclaris

Wednesday, October 17, 2018

Aclaris Acquires Rhofade from Allergan

Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and addit…

Read the full story

Tuesday, May 15, 2018

Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting

Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orland…

Read the full story

Monday, April 23, 2018

First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topical

Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition char…

Read the full story

Friday, April 06, 2018

Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canada

Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 4…

Read the full story

Thursday, March 29, 2018

Hydrogen Peroxide 40% Less Cytotoxic Than Cryotherapy: Study

Hydrogen peroxide topical solution 40% (Eskata, Aclaris) is less cytotoxic to living cells and less damaging to melanocytes than cryosurgery, according to a new study led by Adam Friedman, MD, associa…

Read the full story

Friday, March 09, 2018

Aclaris Therapeutics Receives US Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders

The United States Patent and Trademark Office (USPTO) issued US Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for t…

Read the full story